All In Biotech

Drug Trial Radar · NCT05026398

Fenfluramine and Cognition

The Effect of Seven Day Fenfluramine Administration on Cognition in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Nov 15, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Apr 12, 2021

Primary completion

Jun 22, 2022

Study completion Jun 22, 2022

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.; National Institute for Health Research, United Kingdom
First posted
Aug 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 22 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

In this study, the investigators will investigate the cognitive effects of fenfluramine, a drug that directly stimulates the release of serotonin in the brain and positively modulates σ1 function. The investigators will use fenfluramine to assess the cognitive effects of modulating serotonin and σ1 function in healthy volunteers using a battery of cognitive tasks that measure learning and memory, executive functioning, reward processing, and emotional processing. The study design is double-blind, and participants will be randomised to either seven days of fenfluramine or placebo administration. All participants will attend two screening visits to assess eligibility. There are two main study visits; during the first, participants will undertake cognitive tasks and questionnaires before taking the initial study dose. One the second study visit, participants will once again complete these tasks and questionnaires after a week of fenfluramine/placebo administration.

Conditions

  • Cognitive Function

Interventions

  • FenfluramineDrug

    Fenfluramine (30mg daily) will be dispensed in a cherry flavoured aqueous solution. Fenfluramine is both a serotonin releasing agent and sigma-1 receptor agonist. Fenfluramine is FDA approved for the treatment of Dravet syndrome, a rare form of epilepsy.

  • PlaceboOther

    The placebo is a liquid designed to be identical to the interventional drug fenfluramine in terms of both taste and visual appearance. It will be administered at 30mg daily and dispensed in a cherry flavoured aqueous solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Go/No-Go Task performanceTime frame: Immediately before initial dose (Day 1) and immediately before final visit (Day 7)
  2. Change in Auditory Verbal Learning TaskTime frame: Immediately before initial dose (Day 1) and immediately before final visit (Day 7)
  3. Change in N-back task performanceTime frame: Immediately before initial dose (Day 1) and immediately before final visit (Day 7)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Psychiatry, University of Oxford

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.